SODIUM TARTRATE

Molecular Excipient

Mwt. LogP HBD HBA PSA RB CSP3
148.0 -4.8 2 6 121.0 3 0.5
CAS
868188
UNII
QTO9JB4MDD
SYNONYMS
ZINC ID(s)
Availability
Present in 114 ZINC catalogs

Known Active Genes

This compound has been observed to have activity at 10μM or less against the following gene(s).
Name Description Classification
GBA Glucosylceramidase Enzyme / Enzyme-Other

Clinical Trials

This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
Code Date Title Phase Status
NCT02023866 2014-06-01 Open-Label, Dose-Escalating Study to Assess Safety, Tolerability, Efficacy, PK and PD of RP103 in Children With Inherited Mitochondrial Disease Phase 2/Phase 3 Recruiting
NCT01749982 2012-12-01 A Preliminary Study of Choline and Betaine Supplementation Among Adults Exposed to Arsenic in Bangladesh Phase 4 Completed
NCT01529268 2012-06-01 Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children Phase 2/Phase 3 Active, Not Recruiting
NCT01197378 2010-08-01 Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) Phase 3 Active, Not Recruiting
NCT01149538 2010-07-01 Postnatal Choline Supplementation in Children With Prenatal Alcohol Exposure Phase 1/Phase 2 Completed
NCT01000961 2010-06-01 Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis Phase 3 Completed
NCT02170896 2001-10-01 Bioavailability of BIBR 963 ZW After 50 mg of BIBR 1048 MS With and Without of Pantoprazole in Healthy Subjects Phase 1 Completed

(Browse) Purchasable Analogs in ZINC

Functions of Sodium Tartrate

Misc - Miscellaneous

Regulatory Status of Sodium Tartrate

Gras - Generally recognized as safe.
SODIUM TARTRATE

Dosages

Route Formulation Per Unit Dose
Im - Iv Injection 1.2%
Intramuscular Injection 1.41%
Intravenous Injection 1.2%
Iv(infusion) Injection 1.2%

More Information

Usage Over Time

Data provided by OpenFDA

Comments